Prelude Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
PRLD$3.760.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| (in thousands, except share and per share data) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $12,474 | $25,291 |
| Marketable securities | 121,140 | 207,644 |
| Prepaid expenses and other current assets | 2,281 | 2,654 |
| Total current assets | 135,895 | 235,589 |
| Restricted cash | 4,044 | 4,044 |
| Property and equipment, net | 6,767 | 7,325 |
| Right-of-use asset | 28,699 | 30,412 |
| Prepaid expenses and other non-current assets | 110 | 295 |
| Total assets | $175,515 | $277,665 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $7,732 | $4,580 |
| Accrued expenses and other current liabilities | 15,209 | 15,768 |
| Operating lease liability | 2,492 | 1,481 |
| Finance lease liability | 208 | — |
| Total current liabilities | 25,641 | 21,829 |
| Other liabilities | 3,090 | 3,339 |
| Operating lease liability | 15,325 | 15,407 |
| Total liabilities | 44,056 | 40,575 |
| Commitments (note 8) | ||
| Stockholders’ equity: | ||
| Voting common stock, $0.0001 par value: 487,149,741 shares authorized; 42,298,859 and 42,063,995 shares issued and outstanding at December 31, 2024 and 2023, respectively | 4 | 4 |
| Non-voting common stock, $0.0001 par value: 12,850,259 shares authorized; 12,850,259 shares issued and outstanding at both December 31, 2024 and 2023 | 1 | 1 |
| Additional paid-in capital | 714,982 | 693,252 |
| Accumulated other comprehensive income | 35 | 223 |
| Accumulated deficit | (583,563) | (456,390) |
| Total stockholders’ equity | 131,459 | 237,090 |
| Total liabilities and stockholders’ equity | $175,515 | $277,665 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.